Medco Research
Executive Summary
Joint clinical research program with Bristol-Myers Squibb Diagnostics will study the combination of Medco's Adenoscan, a drug used in conjunction with cardiac imaging, with Squibb's cardiac imaging agent Cardio Tec. Medco says the combo may be superior to the use of exercise stress in conjunction with thallium-201, providing high-quality images in less than one hour. NDAs for both products are pending at FDA. Medco, which has hired investment banker Oppenheimer & Co. to explore the sale of the company ("The Pink Sheet" April 16, T&G-9), says the arrangement does not represent a licensing of any of the firm's rights to Adenoscan, held by Lyphomed.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.